8-[4-(3-Hydroxy-propyl)-bicyclo[2.2.2]oct-1-yl]-1,3-dipropyl-3,7-dihydro-purine-2,6-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 8-[4-(3-Hydroxy-propyl)-bicyclo[2.2.2]oct-1-yl]-1,3-dipropyl-3,7-dihydro-purine-2,6-dione
• 英文别名: 8-[4-(3-hydroxypropyl)-1-bicyclo[2.2.2]octanyl]-1,3-dipropyl-7H-purine-2,6-dione
• 化学式: C₂₂H₃₄N₄O₃
• 分子量: 402.537
• InChiKey: BTPIAWVNHXMYIM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  89.5
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  化合物 T17117 在 ice 、 乙酸乙酯 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 62.0h， 以to afford 345 mg (86%) of a white powder MS的产率得到8-[4-(3-Hydroxy-propyl)-bicyclo[2.2.2]oct-1-yl]-1,3-dipropyl-3,7-dihydro-purine-2,6-dione
  参考文献：
  名称：

  Adenosine receptor antagonists and methods of making and using the same

  摘要：

  该发明基于发现，公式I化合物意外地具有高效和选择性的腺苷A1受体抑制剂。腺苷A1拮抗剂可用于预防和/或治疗许多疾病，包括心脏和循环系统疾病、中枢神经系统退行性疾病、呼吸系统疾病以及许多适合利尿治疗的疾病。在一个实施例中，该发明涉及公式I的化合物：

  公开号：

  US07579354B2

文献信息

• [EN] POLYCYCLOALKYLPURINES AS ADENOSINE RECEPTOR ANTAGONISTS<br/>[FR] POLYCYCLOALKYLPURINES COMME ANTAGONISTES DU RECEPTEUR D'ADENOSINE
  申请人：BIOGEN INC

  公开号：WO2001034610A1

  公开（公告）日：2001-05-17

  The invention is based on the discovery that compounds of Formula (I) are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable. In one embodiment, the invention features a compound of formula (I).

  该发明基于发现，公式（I）化合物是意外的高效、选择性的腺苷A1受体拮抗剂。腺苷A1拮抗剂可用于预防和/或治疗许多疾病，包括心脏和循环系统疾病、中枢神经系统退行性疾病、呼吸系统疾病以及许多适用于利尿治疗的疾病。在一种实施例中，该发明涉及公式（I）化合物。
• ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME
  申请人：Ensinger Carol L.

  公开号：US20090221821A1

  公开（公告）日：2009-09-03

  The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A 1 receptor. Adenosine A 1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable. In one embodiment, the invention features a compound of formula I:

  该发明基于发现，公式I化合物是意外地高效和选择性地抑制腺苷A1受体的抑制剂。腺苷A1拮抗剂可用于预防和/或治疗许多疾病，包括心脏和循环系统疾病，中枢神经系统退行性疾病，呼吸系统疾病以及许多适合利尿治疗的疾病。在一种实施例中，该发明涉及公式I的化合物：
• Polycycloalkylpurines as adenosine receptor antagonists
  申请人：Biogen Idec MA, Inc.

  公开号：EP2070930A1

  公开（公告）日：2009-06-17

  The invention is based on the discovery that compounds of Formula (I) are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable. In one embodiment, the invention features a compound of formula (I).

  本发明的基础是发现式（I）化合物是出乎意料的腺苷 A1 受体的高效选择性抑制剂。腺苷 A1 拮抗剂可用于预防和/或治疗多种疾病，包括心脏和循环系统疾病、中枢神经系统退行性疾病、呼吸系统疾病以及许多适合利尿剂治疗的疾病。在一个实施方案中，本发明以式（I）化合物为特征。
• Poycyloalkylpurines as adenosine receptor antagonists
  申请人：Biogen Idec MA Inc.

  公开号：EP2305684A1

  公开（公告）日：2011-04-06

  The invention is based on the discovery that compounds of Formula (I) are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable. In one embodiment, the invention features a compound of formula (I).

  本发明的基础是发现式（I）化合物是出乎意料的腺苷 A1 受体的高效选择性抑制剂。腺苷 A1 拮抗剂可用于预防和/或治疗多种疾病，包括心脏和循环系统疾病、中枢神经系统退行性疾病、呼吸系统疾病以及许多适合利尿剂治疗的疾病。在一个实施方案中，本发明以式（I）化合物为特征。
• POYCYLOALKYLPURINES AS ADENOSINE RECEPTOR ANTAGONISTS
  申请人：Biogen Idec MA Inc.

  公开号：EP1230243B1

  公开（公告）日：2009-03-04